<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: January 25, 2000
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
- ------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
- ------------------------------------------------------------------------------
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press
release announcing a Product Distribution Agreement with Coherent Laser
Group, Inc. The Press Release, dated January 25, 2000, is attached as Exhibit
99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated January 25, 2000, announcing
a Product Distribution Agreement with Coherent Laser Group, Inc.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
--------------------------------
John Smolik, President
Date: January 25, 2000
<PAGE>
EXHIBIT INDEX
Exhibit Description
No.
99 Press release of the Company, dated January 25, 2000, announcing
a Product Distribution Agreement with Coherent Laser Group, Inc.
<PAGE>
Exhibit 99
PHOTOGEN ANNOUNCES PRODUCT DISTRIBUTION AGREEMENT
WITH COHERENT LASER GROUP
PULSEVIEW-TM- TO BE INTRODUCED AT PHOTONICS WEST JANUARY 22-28
KNOXVILLE, TENN., JAN. 25, 2000 -- Photogen Technologies, Inc. (NASDAQ:
PHGN), developers of non-invasive and minimally invasive therapeutic and
diagnostic technologies, today announced the signing of an exclusive
distribution agreement with Coherent Laser Group, Inc. (NASDAQ: COHR), in
which Coherent will market and sell Photogen's PulseView-TM- software package
and computer interface.
The two-year agreement is a turning point for Photogen Technologies, which
previously was involved only with developmental-stage endeavors. PulseView is
the initial product from Photogen to reach commercial distribution. Coherent
will begin selling PulseView at Photonics West (Jan. 22-28), in San Jose,
Calif.
Also at the show, on Jan. 26, Photogen senior scientist, Eric Wachter, Ph.D.,
will present the latest information about Photogen's melanoma research.
The PulseView package provides a simple, rapid means for characterization and
validation of the performance of ultrafast, pulsed lasers. These advanced
lasers are primarily used for scientific research in spectroscopy, medical,
and materials processing applications. Photogen currently is developing novel
uses for such lasers for multi-photon excitation (MPE), a process which shows
promise for a number of medical applications, including treatment of
melanomas and other cancers using photodynamic therapy.
John Smolik, president and CEO of Photogen, stated, "We created PulseView to
facilitate development of our core medical technologies based on MPE. We view
this contract as a small but significant milestone in our strategy to bring
advanced photodynamic therapy products to the marketplace.
"We are very pleased that Coherent's laser group has chosen to market this
powerful software tool to their sizeable customer base, and look forward to
the possibility of implementing this and other proprietary systems
technologies for a number of applications in the research, materials
processing, and medical laser markets."
<PAGE>
Michael Armas of Coherent Laser Group, stated, "This marketing agreement
resulted from a long-term working relationship we have had with the
scientists at Photogen, and we look forward to the opportunity to offer this
useful product to our customers. It marks an important step for Coherent as
we continue to offer innovations that advance the state-of-the-art in
automation, reliability, ease-of-use of our products and the systems that
they are integrated into."
About Photogen
Photogen Technologies, Inc. is a development-stage company focused on
creating therapeutic and diagnostic products based on its proprietary
multi-photon and other related technologies. The company has discovered new
methods for using energy from lasers, x-rays or other sources to activate
photoactive agents within tissue sufficient to produce a range of beneficial
therapeutic and diagnostic outcomes. These technologies involve methods,
materials and devices that may be used to produce light or other energy and
photoactive agents and to destroy diseased cells, remove tissue or identify
and diagnose disease. Photogen has U.S. patents and additional pending
applications in the U.S. and worldwide for certain of its proprietary
technology.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks and uncertainties include: the ability of the company to
develop a product and obtain regulatory approval for its use; the ability of
the company to successfully market and sell any products and equipment; the
company's ability to manufacture products in sufficient quantities; the
company's ability to maintain intellectual property protection for its
proprietary products, to defend its existing intellectual property rights
from challenges by third parties, and to avoid infringing intellectual
property rights of third parties; unforeseen operating risks; the company's
ability to secure collaborative agreements with third parties for various
research, development, manufacturing, marketing and other functions;
competition; risks associated with the dependence on manufacturers of the
company's proposed products; the availability of capital to finance planned
activities; and the extent to which the clinicians performing the procedures
are able to obtain third-party reimbursement. These risks are qualified in
their entirety by cautionary language and risk factors set forth in the
company's filings with the Securities and Exchange Commission.
Media Contacts: Hilary Kaye or Joan Murray at Hilary Kaye Associates
(714) 426-0444 (PST) or [email protected].
Investor Relations Contact: Jonathan Fassberg at The Trout Group (212)
477-9007 (EST) or [email protected].
